role in shared decision-making, ensuring their treatment plan is truly patient-centered.” “The NCCN Guidelines for Patients: Prostate Cancer outlines essential information about diagnosis and treatment in a comprehensible format. It serves as a
Search Results
language barriers often face added difficulties when participating in shared decision-making. Some patients face conscious or unconscious biases that can have a big impact on their treatment options. “People always say that ‘cancer doesn't discriminate
Dayna S. Early and Darrell M. Gray II
high risk were more likely to prefer shared decision-making with their provider. Felsen et al 17 studied how risk factors for CRC and life-style factors that increase CRC risk (diabetes, smoking, obesity) influenced participation in CRCS in a large
Elizabeth A. Nardi, James McCanney, Katy Winckworth-Prejsnar, Alyssa A. Schatz, Kerin Adelson, Marcus Neubauer, Mary Lou Smith, Ronald Walters, and Robert W. Carlson
preferences and values, the patient experience, patient engagement through shared decision-making, and patient outcomes based on patients' preferences and values. 2 Patient perception of treatment positively correlates with survival rates and overall
Stephen A. Rosenberg, David Francis, Craig R. Hullett, Zachary S. Morris, Michael M. Fisher, Jeffrey V. Brower, Kristin A. Bradley, Bethany M. Anderson, Michael F. Bassetti, and Randall J. Kimple
Background Patient-centered medicine is a cornerstone of 21st century health care in the United States. At the center of this ideal lies shared decision-making between physician and patient. This process is essential in oncology, where
providers so they can engage in shared decision-making about their care.” Patients and caregivers can access NCCN Guidelines for Patients for free at NCCN.org/patientguidelines and via the NCCN Patient Guides for Cancer App. The patient guidelines cover
Guidelines have been developed by experts in the field to share decision-making recommendations with all pediatric oncologists for the best treatment of these lymphomas.” “These new recommendations from NCCN represent one of the first guidelines developed
Kah Poh Loh, Vivian Lam, Katey Webber, Simran Padam, Mina S. Sedrak, Vivek Musinipally, Madison Grogan, Carolyn J. Presley, Janice Grandi, Chandrika Sanapala, Daniel A. Castillo, Grace DiGiovanni, Supriya G. Mohile, Louise C. Walter, and Melisa L. Wong
characteristics are associated with these changes can inform shared decision-making to individualize cancer care. Identifying which patients are at highest risk of functional decline is necessary to weigh the potential benefits and harms of treatment options, to
Ann M. Berger and Kathi Mooney
approaches to the screening, evaluation, and management of CRF and other symptoms in clinical settings. When patients report moderate to severe CRF, clinicians can conduct the “NCCN Primary Evaluation” and use shared decision-making with patients to select an
Ashley E. Ross
; metastasis-free survival rates were 97% and 96%, respectively. 12 “These tests have prognostic value and may be useful for shared decision-making, but genomic signatures that are predictive for treatment response will ultimately have more value.” These
